Karuna Therapeutics to present new data from EMERGENT clinical program

Karuna Therapeutics announced it will be presenting new secondary efficacy, safety and tolerability, and pooled cognition data from its EMERGENT clinical program evaluating KarXT in schizophrenia. The data will be presented at the upcoming 36th European College of Neuropsychopharmacology Congress, to be held October 7-10, 2023, in Barcelona, Spain. “We’re eager to share these latest results, which further support KarXT’s differentiated safety and tolerability profile demonstrated in trials conducted to date and reinforce its potential to provide a broad range of clinically meaningful symptom improvements,” said Stephen Brannan, M.D., chief medical officer of Karuna Therapeutics. “The complex challenges of schizophrenia underscore the urgent need for innovation. We look forward to translating this data into a potentially transformative treatment option for the millions of adults living with this serious, often-debilitating mental illness.”